0001209191-21-052518.txt : 20210819
0001209191-21-052518.hdr.sgml : 20210819
20210819160342
ACCESSION NUMBER: 0001209191-21-052518
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20210815
FILED AS OF DATE: 20210819
DATE AS OF CHANGE: 20210819
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Shani Eli
CENTRAL INDEX KEY: 0001876642
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-16174
FILM NUMBER: 211190121
MAIL ADDRESS:
STREET 1: C/O TEVA
STREET 2: 5 BASEL STREET, P.O. BOX 3190
CITY: PETACH TIKVA
STATE: L3
ZIP: 4951033
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: TEVA PHARMACEUTICAL INDUSTRIES LTD
CENTRAL INDEX KEY: 0000818686
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L3
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5 BAZEL ST
STREET 2: P O B 3190
CITY: PETACH TIKVA
STATE: L3
ZIP: 49131
BUSINESS PHONE: 9729267267
MAIL ADDRESS:
STREET 1: TEVA PHARMACEUTICAL INDUSTRIES LIMITED
STREET 2: 5 BAZEL ST PO B 3190
CITY: PETACH TIKVA
STATE: L3
ZIP: 49131
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2021-08-15
0
0000818686
TEVA PHARMACEUTICAL INDUSTRIES LTD
TEVA
0001876642
Shani Eli
C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.
124 DVORA HANEVI'A ST.,
TEL AVIV
L3
6944020
ISRAEL
0
1
0
0
EVP,Global Marketing&Portfolio
Ordinary Shares
9091
D
Restricted Share Units
Ordinary Shares
6346
D
Restricted Share Units
Ordinary Shares
1581
D
Restricted Share Units
Ordinary Shares
23586
D
Restricted Share Units
Ordinary Shares
15934
D
Stock Options (right to buy)
22.48
2028-08-10
Ordinary Shares
16503
D
Stock Options (right to buy)
34.70
2027-03-03
Ordinary Shares
13002
D
Stock Options (right to buy)
53.50
2026-03-17
Ordinary Shares
13005
D
Stock Options (right to buy)
60.21
2025-03-12
Ordinary Shares
14252
D
Stock Options (right to buy)
48.76
2024-03-12
Ordinary Shares
15002
D
Stock Options (right to buy)
38.08
2023-02-24
Ordinary Shares
4170
D
Stock Options (right to buy)
44.59
2022-02-24
Ordinary Shares
2669
D
The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Restricted share units were granted on March 4, 2019, with 3,173 vesting on each of March 4 2022 and March 4, 2023.
Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
Restricted share units were granted on August 10, 2018, with 1,581 vesting on August 10, 2022.
Restricted share units were granted on March 5, 2021, with 5,896 vesting on each of March 5, 2022, March 5, 2023 and March 5, 2024 and 5,898 vesting on March 5, 2025.
Restricted share units were granted on February 28, 2020, with 5,311 vesting on each of February 28, 2022 and February 28, 2023 and 5,312 vesting on February 28, 2024.
Stock options were granted on August 10, 2018, with 4,152 vesting on each of August 10, 2019, August 10, 2020 and August 10, 2021 and 4,128 vesting on August 10, 2022.
Stock options were granted on March 3, 2017, with 3,250 vested on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 3,252 vested on March 3, 2021.
Stock options were granted on March 17, 2016, with 3,251 vested on each of March 17, 2017, March 17, 2018 and March 17, 2019 and 3,252 vested on March 17, 2020.
Stock options were granted on March 12, 2015, with 3,563 vested on each of March 12, 2016, March 12, 2017, March 12, 2018 and March 12, 2019.
Stock options were granted on March 12, 2014, with 5,000 vested on each of March 12, 2015 and March 12, 2016 and 5,002 vested on March 12, 2017.
Stock options were granted on February 24, 2013, with 4,170 having vested on February 24, 2016.
Stock options were granted on February 24, 2012, with 2,669 vested on February 24, 2016.
/s/ Dov Bergwerk as attorney-in-fact for Eli Shani
2021-08-19
EX-24.3_1004922
2
poa.txt
POA DOCUMENT
POWER OF ATTORNEY
FOR SECTION 16 REPORTING OBLIGATIONS
KNOW ALL BY THESE PRESENTS, that the undersigned hereby makes, constitutes and
appoints Dov Bergwerk, Dikla Tadmor, Netanel Derovan and Shira Aran-Porat
signing singly, as the undersigneds true and lawful attorney-in-fact, with full
power and authority as hereinafter described on behalf of and in the name, place
and stead of the undersigned to:
(1) prepare, execute, acknowledge, deliver and file Forms 3, 4, and 5 (including
any amendments thereto) with respect to the securities of Teva Pharmaceutical
Industries Limited, a company incorporated under the law of Israel, or any
successor thereto (the "Company"), with the U.S. Securities and Exchange
Commission, any national securities exchanges and the Company, as considered
necessary or advisable under Section 16(a) of the Securities Exchange Act of
1934 and the rules and regulations promulgated thereunder, as amended from time
to time (the "Exchange Act");
(2) seek or obtain, as the undersigneds representative and on the undersigneds
behalf, information of transactions in the Companys securities from any
third-party, including brokers, employee benefit plan administrators and
trustees, and the undersigned hereby authorizes any such person to release any
such information to the undersigned and approves and ratifies any such release
of information; and
(3) perform any and all other acts which in the discretion of such
attorney-in-fact is necessary or desirable for and on behalf of the undersigned
in connection with the foregoing.
The undersigned acknowledges that:
(1) this Power of Attorney authorizes, but does not require, such
attorney-in-fact to act in his or her discretion on information provided to such
attorney-in-fact without independent verification of such information;
(2) any documents prepared, executed, acknowledged and/or delivered by such
attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney
will be in such form and will contain such information and disclosure as such
attorney-in-fact, in his or her discretion, deems necessary or desirable;
(3) neither the Company nor such attorney-in-fact assumes (i) any liability for
the undersigneds responsibility to comply with the requirement of the Exchange
Act, (ii) any liability of the undersigned for any failure to comply with such
requirements or (iii) any obligation or liability of the undersigned for profit
disgorgement under Section 16(b) of the Exchange Act; and
(4) this Power of Attorney does not relieve the undersigned from responsibility
for compliance with the undersigneds obligations under the Exchange Act,
including without limitation the reporting requirements under Section 16 of the
Exchange Act.
The undersigned hereby gives and grants the foregoing attorney-in-fact full
power and authority to do and perform all and every act and thing whatsoever
requisite, necessary or appropriate to be done in and about the foregoing
matters as fully to all intents and purposes as the undersigned might or could
do if present, hereby ratifying all that such attorney-in-fact of, for and on
behalf of the undersigned, shall lawfully do or cause to be done by virtue of
this Power of Attorney.
This Power of Attorney shall remain in full force and effect until revoked by
the undersigned in a signed writing delivered to such attorney-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 1st day of August, 2021.
By: /s/ Eli Shani
Name: Eli Shani
Title: EVP, Global Marketing & Portfolio